Devicor® Medical Products, Inc. (Devicor), a portfolio company of GTCR,
a leading private equity firm, and Faxitron® Bioptics, LLC are pleased
to announce a new distribution agreement for Faxitron's CoreVision® in
the United States and abroad. CoreVision® verifies the presence of
micro-calcifications in core biopsies, rapidly confirming a successful
biopsy procedure directly in the stereotactic biopsy suite.
Faxitron's CoreVision® is sold to breast radiologists, breast surgeons
and clinicians around the world. The use of purpose-built, point-of-care
specimen radiography like Faxitron's CoreVision®, is to minimize patient
discomfort through shorter procedure times that also allow for workflow
efficiencies and more room turns.
"Our strategy is focused on providing best-in-class technology that
increases the accuracy of breast cancer detection while facilitating
more efficient clinical practice," said Devicor CEO Tom Daulton.
"Faxitron's CoreVision® is perfectly aligned with our mission, and is
highly complementary with our current products, including Mammotome
revolve® and the Mammotome MammoTestTM stereotactic biopsy
The agreement includes the newly co-branded Mammotome CoreVision® within
the United States, with impending distribution in other countries in
Europe and Asia.
"This joint venture is one of the most exciting events in our company's
history," said Faxitron CEO Paul Murtagh. "Together, our combined market
presence will help us reach more hospitals and breast centers and
provide the equipment needed to redefine procedural efficiency."
About Faxitron® Biotics, LLC
Faxitron is the world's largest and only fully vertically integrated,
dedicated cabinet x-ray company. With an installed base of over 7,000
systems in medical facilities and scientific and industrial research
laboratories around the globe, Faxitron is the pioneer and industry
standard in cabinet x-ray systems for specimen radiography, research,
and NDT applications. For more than 40 years, Faxitron has defined
cabinet x-ray by developing x-ray sensor technology and innovative
systems to meet the evolving needs of our customers.
About Devicor® Medical Products, Inc.
Devicor Medical Products, headquartered in Cincinnati, Ohio, has more
than 400 employees around the world. As the global market leader,
Devicor is committed to advancing technology to help clinicians
accurately diagnose breast disease, such as breast cancer, through
minimally invasive procedures. Devicor's product portfolio includes the
world-renowned Mammotome® Breast Biopsy System, Mammotome revolve®, the
tetherless Mammotome elite®, Neoprobe® Gamma Detection System (GDS),
Mammotome MammoTestTM stereotactic biopsy table, as well as a
comprehensive portfolio of tissue markers used in breast disease
diagnostic sampling and management. These products are sold in more than
50 countries around the world. Since its introduction in 1995, more than
four million women have had a minimally invasive breast biopsy in
stereotactic, ultrasound or MRI-guidance imaging using the Mammotome®
Breast Biopsy System. For more information, please visit www.devicormedical.com
Founded in 1980, GTCR is a leading private equity firm focused on
investing in growth companies in the Financial Services & Technology,
Healthcare and Information Services & Technology industries. The
Chicago-based firm pioneered The Leaders Strategy™ - finding and
partnering with management leaders in core domains to identify, acquire
and build market-leading companies through transformational acquisitions
and organic growth. Since its inception, GTCR has invested more than $10
billion in over 200 companies. For more information, please visit www.gtcr.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140501006854/en/
[ Back To NFVZone's Homepage ]